Industry Research Reports

Home > Reports > Pharma & Healthcare > Mitochondrial-based Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Mitochondrial-based Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-15

Pages: 101 Pages

Report ld: 2218682

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.

The global market for Mitochondrial-based Therapeutics was estimated to be worth US$ 379 million in 2023 and is forecast to a readjusted size of US$ 651.3 million by 2030 with a CAGR of 7.8% during the forecast period 2024-2030

Mitochondrial-based Therapeutics Market Size

M= millions and B=billions

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Mitochondrial-based Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Mitochondrial-based Therapeutics by region & country, by Type, and by Application.

The Mitochondrial-based Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mitochondrial-based Therapeutics.

Market Segmentation

Report Metric
Details
Report Title
Mitochondrial-based Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 651.3 million
CAGR(2024-2030)
7.8%
Market Size Available for Years
2019-2030
Global Mitochondrial-based Therapeutics Companies Covered
Reneo Pharmaceutical, Pfizer Inc., Norvartis AG, Takeda Pharmaceuticals, Amgen Inc., NeuroVive Pharmaceutical AB, Entogene AG, Stealth Biotherapeutics, Ixchel Pharma, Reata Pharmaceuticals
Global Mitochondrial-based Therapeutics Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Mitochondrial-based Therapeutics Market, Segment by Type
Oral

Intravenous
Global Mitochondrial-based Therapeutics Market, Segment by Application
Mitochondrial Myopathy

Leber’s heredity Optic Neuropathy

Leigh Syndrome

Mitochondrial DNA Depletion Syndrome

Other
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Mitochondrial-based Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Mitochondrial-based Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Mitochondrial-based Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Mitochondrial-based Therapeutics Product Introduction
    1.2 Global Mitochondrial-based Therapeutics Market Size Forecast
    1.3 Mitochondrial-based Therapeutics Market Trends & Drivers
        1.3.1 Mitochondrial-based Therapeutics Industry Trends
        1.3.2 Mitochondrial-based Therapeutics Market Drivers & Opportunity
        1.3.3 Mitochondrial-based Therapeutics Market Challenges
        1.3.4 Mitochondrial-based Therapeutics Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Mitochondrial-based Therapeutics Players Revenue Ranking (2023)
    2.2 Global Mitochondrial-based Therapeutics Revenue by Company (2019-2024)
    2.3 Key Companies Mitochondrial-based Therapeutics Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Mitochondrial-based Therapeutics Product Offered
    2.5 Key Companies Time to Begin Mass Production of Mitochondrial-based Therapeutics
    2.6 Mitochondrial-based Therapeutics Market Competitive Analysis
        2.6.1 Mitochondrial-based Therapeutics Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Mitochondrial-based Therapeutics Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mitochondrial-based Therapeutics as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Oral
        3.1.2 Intravenous
    3.2 Global Mitochondrial-based Therapeutics Sales Value by Type
        3.2.1 Global Mitochondrial-based Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Mitochondrial-based Therapeutics Sales Value, by Type (2019-2030)
        3.2.3 Global Mitochondrial-based Therapeutics Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Mitochondrial Myopathy
        4.1.2 Leber’s heredity Optic Neuropathy
        4.1.3 Leigh Syndrome
        4.1.4 Mitochondrial DNA Depletion Syndrome
        4.1.5 Other
    4.2 Global Mitochondrial-based Therapeutics Sales Value by Application
        4.2.1 Global Mitochondrial-based Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Mitochondrial-based Therapeutics Sales Value, by Application (2019-2030)
        4.2.3 Global Mitochondrial-based Therapeutics Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Mitochondrial-based Therapeutics Sales Value by Region
        5.1.1 Global Mitochondrial-based Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Mitochondrial-based Therapeutics Sales Value by Region (2019-2024)
        5.1.3 Global Mitochondrial-based Therapeutics Sales Value by Region (2025-2030)
        5.1.4 Global Mitochondrial-based Therapeutics Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Mitochondrial-based Therapeutics Sales Value, 2019-2030
        5.2.2 North America Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Mitochondrial-based Therapeutics Sales Value, 2019-2030
        5.3.2 Europe Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Mitochondrial-based Therapeutics Sales Value, 2019-2030
        5.4.2 Asia Pacific Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Mitochondrial-based Therapeutics Sales Value, 2019-2030
        5.5.2 South America Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Mitochondrial-based Therapeutics Sales Value, 2019-2030
        5.6.2 Middle East & Africa Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Mitochondrial-based Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Mitochondrial-based Therapeutics Sales Value
    6.3 United States
        6.3.1 United States Mitochondrial-based Therapeutics Sales Value, 2019-2030
        6.3.2 United States Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Mitochondrial-based Therapeutics Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Mitochondrial-based Therapeutics Sales Value, 2019-2030
        6.4.2 Europe Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Mitochondrial-based Therapeutics Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Mitochondrial-based Therapeutics Sales Value, 2019-2030
        6.5.2 China Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Mitochondrial-based Therapeutics Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Mitochondrial-based Therapeutics Sales Value, 2019-2030
        6.6.2 Japan Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Mitochondrial-based Therapeutics Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Mitochondrial-based Therapeutics Sales Value, 2019-2030
        6.7.2 South Korea Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Mitochondrial-based Therapeutics Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Mitochondrial-based Therapeutics Sales Value, 2019-2030
        6.8.2 Southeast Asia Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Mitochondrial-based Therapeutics Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Mitochondrial-based Therapeutics Sales Value, 2019-2030
        6.9.2 India Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Mitochondrial-based Therapeutics Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Reneo Pharmaceutical
        7.1.1 Reneo Pharmaceutical Profile
        7.1.2 Reneo Pharmaceutical Main Business
        7.1.3 Reneo Pharmaceutical Mitochondrial-based Therapeutics Products, Services and Solutions
        7.1.4 Reneo Pharmaceutical Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.1.5 Reneo Pharmaceutical Recent Developments
    7.2 Pfizer Inc.
        7.2.1 Pfizer Inc. Profile
        7.2.2 Pfizer Inc. Main Business
        7.2.3 Pfizer Inc. Mitochondrial-based Therapeutics Products, Services and Solutions
        7.2.4 Pfizer Inc. Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.2.5 Pfizer Inc. Recent Developments
    7.3 Norvartis AG
        7.3.1 Norvartis AG Profile
        7.3.2 Norvartis AG Main Business
        7.3.3 Norvartis AG Mitochondrial-based Therapeutics Products, Services and Solutions
        7.3.4 Norvartis AG Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.3.5 Takeda Pharmaceuticals Recent Developments
    7.4 Takeda Pharmaceuticals
        7.4.1 Takeda Pharmaceuticals Profile
        7.4.2 Takeda Pharmaceuticals Main Business
        7.4.3 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Products, Services and Solutions
        7.4.4 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.4.5 Takeda Pharmaceuticals Recent Developments
    7.5 Amgen Inc.
        7.5.1 Amgen Inc. Profile
        7.5.2 Amgen Inc. Main Business
        7.5.3 Amgen Inc. Mitochondrial-based Therapeutics Products, Services and Solutions
        7.5.4 Amgen Inc. Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.5.5 Amgen Inc. Recent Developments
    7.6 NeuroVive Pharmaceutical AB
        7.6.1 NeuroVive Pharmaceutical AB Profile
        7.6.2 NeuroVive Pharmaceutical AB Main Business
        7.6.3 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Products, Services and Solutions
        7.6.4 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.6.5 NeuroVive Pharmaceutical AB Recent Developments
    7.7 Entogene AG
        7.7.1 Entogene AG Profile
        7.7.2 Entogene AG Main Business
        7.7.3 Entogene AG Mitochondrial-based Therapeutics Products, Services and Solutions
        7.7.4 Entogene AG Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.7.5 Entogene AG Recent Developments
    7.8 Stealth Biotherapeutics
        7.8.1 Stealth Biotherapeutics Profile
        7.8.2 Stealth Biotherapeutics Main Business
        7.8.3 Stealth Biotherapeutics Mitochondrial-based Therapeutics Products, Services and Solutions
        7.8.4 Stealth Biotherapeutics Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.8.5 Stealth Biotherapeutics Recent Developments
    7.9 Ixchel Pharma
        7.9.1 Ixchel Pharma Profile
        7.9.2 Ixchel Pharma Main Business
        7.9.3 Ixchel Pharma Mitochondrial-based Therapeutics Products, Services and Solutions
        7.9.4 Ixchel Pharma Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.9.5 Ixchel Pharma Recent Developments
    7.10 Reata Pharmaceuticals
        7.10.1 Reata Pharmaceuticals Profile
        7.10.2 Reata Pharmaceuticals Main Business
        7.10.3 Reata Pharmaceuticals Mitochondrial-based Therapeutics Products, Services and Solutions
        7.10.4 Reata Pharmaceuticals Mitochondrial-based Therapeutics Revenue (US$ Million) & (2019-2024)
        7.10.5 Reata Pharmaceuticals Recent Developments

 8 Industry Chain Analysis
    8.1 Mitochondrial-based Therapeutics Industrial Chain
    8.2 Mitochondrial-based Therapeutics Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Mitochondrial-based Therapeutics Sales Model
        8.5.2 Sales Channel
        8.5.3 Mitochondrial-based Therapeutics Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Mitochondrial-based Therapeutics Market Trends
    Table 2. Mitochondrial-based Therapeutics Market Drivers & Opportunity
    Table 3. Mitochondrial-based Therapeutics Market Challenges
    Table 4. Mitochondrial-based Therapeutics Market Restraints
    Table 5. Global Mitochondrial-based Therapeutics Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Mitochondrial-based Therapeutics Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Mitochondrial-based Therapeutics Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Mitochondrial-based Therapeutics Product Type
    Table 9. Key Companies Time to Begin Mass Production of Mitochondrial-based Therapeutics
    Table 10. Global Mitochondrial-based Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mitochondrial-based Therapeutics as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Mitochondrial-based Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Mitochondrial-based Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Mitochondrial-based Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Mitochondrial-based Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Mitochondrial-based Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Mitochondrial-based Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Mitochondrial-based Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Mitochondrial-based Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Mitochondrial-based Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Mitochondrial-based Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Mitochondrial-based Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Mitochondrial-based Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Mitochondrial-based Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Mitochondrial-based Therapeutics Sales Value by Region (2019-2024) & (%)
    Table 27. Global Mitochondrial-based Therapeutics Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Mitochondrial-based Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Mitochondrial-based Therapeutics Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Mitochondrial-based Therapeutics Sales Value, (2025-2030) & (US$ Million)
    Table 31. Reneo Pharmaceutical Basic Information List
    Table 32. Reneo Pharmaceutical Description and Business Overview
    Table 33. Reneo Pharmaceutical Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Reneo Pharmaceutical (2019-2024)
    Table 35. Reneo Pharmaceutical Recent Developments
    Table 36. Pfizer Inc. Basic Information List
    Table 37. Pfizer Inc. Description and Business Overview
    Table 38. Pfizer Inc. Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Pfizer Inc. (2019-2024)
    Table 40. Pfizer Inc. Recent Developments
    Table 41. Norvartis AG Basic Information List
    Table 42. Norvartis AG Description and Business Overview
    Table 43. Norvartis AG Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Norvartis AG (2019-2024)
    Table 45. Norvartis AG Recent Developments
    Table 46. Takeda Pharmaceuticals Basic Information List
    Table 47. Takeda Pharmaceuticals Description and Business Overview
    Table 48. Takeda Pharmaceuticals Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Takeda Pharmaceuticals (2019-2024)
    Table 50. Takeda Pharmaceuticals Recent Developments
    Table 51. Amgen Inc. Basic Information List
    Table 52. Amgen Inc. Description and Business Overview
    Table 53. Amgen Inc. Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Amgen Inc. (2019-2024)
    Table 55. Amgen Inc. Recent Developments
    Table 56. NeuroVive Pharmaceutical AB Basic Information List
    Table 57. NeuroVive Pharmaceutical AB Description and Business Overview
    Table 58. NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of NeuroVive Pharmaceutical AB (2019-2024)
    Table 60. NeuroVive Pharmaceutical AB Recent Developments
    Table 61. Entogene AG Basic Information List
    Table 62. Entogene AG Description and Business Overview
    Table 63. Entogene AG Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Entogene AG (2019-2024)
    Table 65. Entogene AG Recent Developments
    Table 66. Stealth Biotherapeutics Basic Information List
    Table 67. Stealth Biotherapeutics Description and Business Overview
    Table 68. Stealth Biotherapeutics Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Stealth Biotherapeutics (2019-2024)
    Table 70. Stealth Biotherapeutics Recent Developments
    Table 71. Ixchel Pharma Basic Information List
    Table 72. Ixchel Pharma Description and Business Overview
    Table 73. Ixchel Pharma Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Ixchel Pharma (2019-2024)
    Table 75. Ixchel Pharma Recent Developments
    Table 76. Reata Pharmaceuticals Basic Information List
    Table 77. Reata Pharmaceuticals Description and Business Overview
    Table 78. Reata Pharmaceuticals Mitochondrial-based Therapeutics Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Mitochondrial-based Therapeutics Business of Reata Pharmaceuticals (2019-2024)
    Table 80. Reata Pharmaceuticals Recent Developments
    Table 81. Key Raw Materials Lists
    Table 82. Raw Materials Key Suppliers Lists
    Table 83. Mitochondrial-based Therapeutics Downstream Customers
    Table 84. Mitochondrial-based Therapeutics Distributors List
    Table 85. Research Programs/Design for This Report
    Table 86. Key Data Information from Secondary Sources
    Table 87. Key Data Information from Primary Sources
    Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Mitochondrial-based Therapeutics Product Picture
    Figure 2. Global Mitochondrial-based Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Mitochondrial-based Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 4. Mitochondrial-based Therapeutics Report Years Considered
    Figure 5. Global Mitochondrial-based Therapeutics Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Mitochondrial-based Therapeutics Revenue in 2023
    Figure 7. Mitochondrial-based Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Oral Picture
    Figure 9. Intravenous Picture
    Figure 10. Global Mitochondrial-based Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Mitochondrial-based Therapeutics Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Mitochondrial Myopathy
    Figure 13. Product Picture of Leber’s heredity Optic Neuropathy
    Figure 14. Product Picture of Leigh Syndrome
    Figure 15. Product Picture of Mitochondrial DNA Depletion Syndrome
    Figure 16. Product Picture of Other
    Figure 17. Global Mitochondrial-based Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 18. Global Mitochondrial-based Therapeutics Sales Value Market Share by Application, 2023 & 2030
    Figure 19. North America Mitochondrial-based Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 20. North America Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 21. Europe Mitochondrial-based Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 22. Europe Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 23. Asia Pacific Mitochondrial-based Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 24. Asia Pacific Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 25. South America Mitochondrial-based Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 26. South America Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 27. Middle East & Africa Mitochondrial-based Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 28. Middle East & Africa Mitochondrial-based Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 29. Key Countries/Regions Mitochondrial-based Therapeutics Sales Value (%), (2019-2030)
    Figure 30. United States Mitochondrial-based Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 31. United States Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 32. United States Mitochondrial-based Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 33. Europe Mitochondrial-based Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 34. Europe Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 35. Europe Mitochondrial-based Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 36. China Mitochondrial-based Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 37. China Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 38. China Mitochondrial-based Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 39. Japan Mitochondrial-based Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 40. Japan Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 41. Japan Mitochondrial-based Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 42. South Korea Mitochondrial-based Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 43. South Korea Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 44. South Korea Mitochondrial-based Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 45. Southeast Asia Mitochondrial-based Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 47. Southeast Asia Mitochondrial-based Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 48. India Mitochondrial-based Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 49. India Mitochondrial-based Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 50. India Mitochondrial-based Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 51. Mitochondrial-based Therapeutics Industrial Chain
    Figure 52. Mitochondrial-based Therapeutics Manufacturing Cost Structure
    Figure 53. Channels of Distribution (Direct Sales, and Distribution)
    Figure 54. Bottom-up and Top-down Approaches for This Report
    Figure 55. Data Triangulation

Description

Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.

The global market for Mitochondrial-based Therapeutics was estimated to be worth US$ 379 million in 2023 and is forecast to a readjusted size of US$ 651.3 million by 2030 with a CAGR of 7.8% during the forecast period 2024-2030

Market Segmentation